Subtype
High-Grade Glioma, NOS
CI-CAN-00009391Explore in graph →
75 active trials2 approved drugs11 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00009391Explore in graph →
Clinical trials
173 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (30)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05929456 | Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)(MIRROR) | unknown | Phase 1 | 21 | University Medical Center GroningenOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03411408 | Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent High Grade Glioma.(HBO-RT) | unknown | N/A | 24 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
| 1 |
| May 30, 2023 |
| clinicaltrials |
| NCT05850377 | 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas | unknown | — | 90 | Sociedad de Lucha Contra el Cáncer del EcuadorOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT04908267 | How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas | unknown | — | 100 | Weiguo ZhangOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT05630664 | Liquid Biopsy in High-grade Gliomas and Meningiomas(SOPRANO) | unknown | — | 90 | IRCCS San RaffaeleOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT04822805 | A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma | unknown | Phase 2 | 27 | First People's Hospital of HangzhouOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT04588987 | Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02239952 | HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors) | unknown | N/A | 15 | Amsterdam UMC, location VUmcOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03392545 | Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1)(InSituVac1) | unknown | Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT02848794 | Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma | unknown | Phase 1 / Phase 2 | 40 | The First People's Hospital of LianyungangOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT02416999 | Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas | unknown | N/A | 30 | Hebei Yanda HospitalOTHER | 1 | Feb 18, 2016 | clinicaltrials |
| NCT02333513 | A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation | unknown | N/A | 100 | Hebei Yanda HospitalOTHER | 1 | Apr 9, 2015 | clinicaltrials |
| NCT01499823 | Permeability Map to Distinguish Progression From Pseudoprogression in High-Grade Glioma | unknown | — | 74 | Seoul National University HospitalOTHER | 1 | Dec 30, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jul 3, 2023source: clinicaltrials